{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T18:48:22Z","timestamp":1780598902635,"version":"3.54.1"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,2,18]],"date-time":"2021-02-18T00:00:00Z","timestamp":1613606400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,2,18]],"date-time":"2021-02-18T00:00:00Z","timestamp":1613606400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1007\/s12032-021-01477-y","type":"journal-article","created":{"date-parts":[[2021,2,19]],"date-time":"2021-02-19T10:10:36Z","timestamp":1613729436000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Sarcoid-like reaction in cases treated by checkpoint inhibitors"],"prefix":"10.1007","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4642-3693","authenticated-orcid":false,"given":"Semra","family":"Paydas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,18]]},"reference":[{"key":"1477_CR1","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.amjsurg.2009.01.004","volume":"197","author":"BM Hunt","year":"2009","unstructured":"Hunt BM, Valliers E, Buduhan G, Aye R, Louie B. Sarcoidosis as a benign cause of lymphadenopathy in cancer patients. Am J Surg. 2009;197:629\u201332.","journal-title":"Am J Surg"},{"key":"1477_CR2","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.clindermatol.2007.03.010","volume":"25","author":"PR Cohen","year":"2007","unstructured":"Cohen PR, Kurzrock R. Sarcoidosis and malignancy. Clin Dermatol. 2007;25:326\u201333.","journal-title":"Clin Dermatol"},{"key":"1477_CR3","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/S0145-2126(02)00070-X","volume":"26","author":"S Paydas","year":"2002","unstructured":"Paydas S, Yavuz S, Disel U, Zeren H, Hast\u00fcrk S, Hanta I, Ergin M, Sahin B. Granulomatous reaction after chemotherapy for Hodgkin\u2019s disease. Leuk Res. 2002;26:967\u201370.","journal-title":"Leuk Res"},{"key":"1477_CR4","doi-asserted-by":"crossref","first-page":"249","DOI":"10.3892\/mco.2014.422","volume":"3","author":"N Suditu","year":"2015","unstructured":"Suditu N, Negru D. Bacillus Calmette\u2013Guerin therapy-associated granulomatous prostatitis mimicking prostate cancer on MRI: a case report and literature review. Mol Clin Oncol. 2015;3:249\u201351.","journal-title":"Mol Clin Oncol"},{"key":"1477_CR5","doi-asserted-by":"crossref","first-page":"316","DOI":"10.20344\/amp.10250","volume":"32","author":"V Clerigo","year":"2019","unstructured":"Clerigo V, Castro A, Mourato T, Gomes C. A rare case of granulomatous pneumonitis due to intravesical BCG for bladder cancer. Acta Med Port. 2019;32:316\u201320.","journal-title":"Acta Med Port"},{"key":"1477_CR6","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1159\/000161122","volume":"218","author":"A Eckert","year":"2009","unstructured":"Eckert A, Schoeffler A, Dalle S, Phan A, Kiakouama L, Thomas L. Anti-CTLA4 monoclonal antibody induced sarcoidosis in a metastatic melanoma patient. Dermatology. 2009;218:69\u201370.","journal-title":"Dermatology"},{"key":"1477_CR7","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.chest.2015.10.082","volume":"149","author":"FX Danlos","year":"2016","unstructured":"Danlos FX, Pages C, Baroudjian B, Vercellino L, Battistella M, Mimoun M, Jebali M, Bagot M, Tazi A, Lebbe C. Nivolumab-induced sarcoid-like granulomatous reaction in a patient with advanced melanoma. Chest. 2016;149:133\u20136.","journal-title":"Chest"},{"key":"1477_CR8","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1158\/2326-6066.CIR-15-0102","volume":"3","author":"SH Tirumani","year":"2015","unstructured":"Tirumani SH, Ramaiya NH, Keraliya A, Bailey ND, Ott PA, Hodi FS Nishino M. Radiographic profiling of immune-related adverse events in advanced melanoma patients treated with ipilimumab. Cancer Immunol Res. 2015;3:1185\u201392.","journal-title":"Cancer Immunol Res"},{"key":"1477_CR9","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1136\/thx.2010.140319","volume":"66","author":"M Facco","year":"2011","unstructured":"Facco M, Cabrelle A, Teramo A, Olivieri V, Gnoato M, Teolato S, Ave E, Gattazzo C, Fadini GP, Calabrese F, Semenzato G, Agostini C. Sarcoidosis is a Th1\/Th17 multisystem disorder. Thorax. 2011;66:144\u201350.","journal-title":"Thorax"},{"key":"1477_CR10","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1093\/rheumatology\/ker316","volume":"51","author":"B Ten Berge","year":"2012","unstructured":"Ten Berge B, Paats MS, Bergen IM, van den Blink B, Hoogsteden HC, Lambrecht BN, Hendriks RW, Kleinjan A. Increased IL17A expression in granulomas and in circulating memory T cells in sarcoidosis. Rheumatology. 2012;51:37\u201346.","journal-title":"Rheumatology"},{"key":"1477_CR11","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1164\/ajrccm.159.6.9807152","volume":"159","author":"JM Naccache","year":"1999","unstructured":"Naccache JM, Antoine M, Wislez M, Fleury-Feith J, Oksenhendler E, Mayaud C, Cadranel J. Sarcoid-like pulmonary disorder in human immunodeficiency virus-infected patients receiving antiretroviral therapy. Am J Respir Crit Care Med. 1999;159:2009\u201313.","journal-title":"Am J Respir Crit Care Med"},{"issue":"7","key":"1477_CR12","first-page":"4428","volume":"7","author":"M Ishida","year":"2014","unstructured":"Ishida M, Hodohara K, Furuya A, Okuno H, Yoshii M, Horinouchi A, Yoshida T. Sarcoidal granulomas in the mediastinal lymph nodes after treatment for marginal zone lymphoma of the esophagus: report of a case with review of the concept of the sarcoidosis-lymphoma syndrome. Int J Clin Exp Pathol. 2014;7(7):4428\u201332.","journal-title":"Int J Clin Exp Pathol"},{"key":"1477_CR13","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1038\/ni1467","volume":"8","author":"EV Acosta-Rodriguez","year":"2007","unstructured":"Acosta-Rodriguez EV, Rivino L, Geginat J, Jarrossay D, Gattorno M, Lanzavecchia A, Sallusto F, Napolitani G. Surface phenotype and antigenic specificity of human interleukin 17-producing T helper memory cells. Nat Immunol. 2007;8:639\u201346.","journal-title":"Nat Immunol"},{"key":"1477_CR14","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1084\/jem.20130301","volume":"211","author":"R Ramesh","year":"2014","unstructured":"Ramesh R, Kozhaya L, McKevitt K, Djuretic IM, Carlson TJ, Quintero MA, McCauley JL, Abreu MT, Unutmaz D, Sundrud MS. Pro-inflammatory human Th17 cells selectively express P-glycoprotein and are refractory to glucocorticoids. J Exp Med. 2014;211:89\u2013104.","journal-title":"J Exp Med"},{"key":"1477_CR15","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1164\/rccm.201507-1499OC","volume":"193","author":"J Ramstein","year":"2016","unstructured":"Ramstein J, Broos CE, Simpson LJ, Ansel KM, Sun SA, Ho ME, Woodruff PG, Bhakta NR, Christian L, Nguyen CP, Antalek BJ, Benn BS, Hendriks RW, van den Blink B, Kool M, Koth LL. IFN-gamma-producing T-helper 17.1 cells are increased in sarcoidosis and are more prevalent than T-helper type 1 cells. Am J Respir Crit Care Med. 2016;193:1281\u201391.","journal-title":"Am J Respir Crit Care Med"},{"key":"1477_CR16","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1111\/1756-185X.13076","volume":"20","author":"AJ Lomax","year":"2017","unstructured":"Lomax AJ, Mcguire HM, Mcneil C, Choi CJ, Hersey P, Karikios D, Shannon K, Van Hal S, Carr U, Crotty A, Gupta SK, Hollingsworth J, Kim H, Groth BF, Mcgill N. Immunotherapy-induced sarcoidosis in patients with melanoma treated with PD-1 checkpoint inhibitors: case series and immunophenotypic analysis. Int J Rheum Dis. 2017;20:1277\u201385.","journal-title":"Int J Rheum Dis"},{"key":"1477_CR17","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1164\/rccm.201401-0188OC","volume":"190","author":"NA Braun","year":"2014","unstructured":"Braun NA, Celada LJ, Herazo-Maya JD, Abraham S, Shaginurova G, Sevin CM, Grutters J, Culver DA, Dworski R, Sheller J, Massion PP, Polosukhin VV, Johnson JE, Kaminski N, Wilkes DS, Oswald-Richter KA, Drake WP. Blockade of the programmed death-1 pathway restores sarcoidosis CD4(+) T cell proliferative capacity. Am J Respir Care Med. 2014;190:560\u201371.","journal-title":"Am J Respir Care Med"},{"key":"1477_CR18","first-page":"328","volume":"8","author":"W Zou","year":"2016","unstructured":"Zou W, Wolchok JD, Chen L. PD-L1 (B7eH1) and PD-1 pathway blockade for cancer therapy: mechanisms, response biomarkers and combinations. Sci Transl Med. 2016;8:328.","journal-title":"Sci Transl Med"},{"key":"1477_CR19","first-page":"133","volume":"85","author":"S Saidha","year":"2012","unstructured":"Saidha S, Sotirchos ES, Eckstein C. Etiology of sarcoidosis: does infection play a role? Yale J Biol Med. 2012;85:133\u201341.","journal-title":"Yale J Biol Med"},{"key":"1477_CR20","first-page":"126","volume":"22","author":"M Al-dliw","year":"2017","unstructured":"Al-dliw M, Megri M, Shahoub I, Sahay G, Limjoco TI, Shweihat Y. Pembrolizumab reactivates pulmonary granulomatosis. Respir Med Case Rep. 2017;22:126\u20139.","journal-title":"Respir Med Case Rep"},{"key":"1477_CR21","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.jdcr.2016.06.004","volume":"2","author":"J Cotliar","year":"2016","unstructured":"Cotliar J, Querfeld C, Boswell WJ, Raja N, Raz D, Chen R. Pembrolizumab associated sarcoidosis. JAAD Case Rep. 2016;2:290\u20133.","journal-title":"JAAD Case Rep"},{"key":"1477_CR22","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1001\/jamadermatol.2017.0581","volume":"153","author":"S Burillo-Martinez","year":"2017","unstructured":"Burillo-Martinez S, MoralesRaya C, Prieto-Barrios M, Rodriguez-Peralto JL, Ortiz-Romero P-L. Pembrolizumab-induced extensive panniculitis and nevus regression: two novel cutaneous manifestations of the post-immunotherapy granulomatous reactions spectrum. JAMA Dermatol. 2017;153:721\u20132.","journal-title":"JAMA Dermatol"},{"key":"1477_CR23","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1111\/ijd.13984","volume":"57","author":"AT Lopez","year":"2018","unstructured":"Lopez AT, Khana T, Antonov N, Audrey-Bayan C, Geskin L. A review of bullous pemphigoid associated with PD-1 and PD-L1 inhibitors. Int J Dermatol. 2018;57:664\u20139.","journal-title":"Int J Dermatol"},{"key":"1477_CR24","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1111\/jdv.14617","volume":"32","author":"J Wu","year":"2018","unstructured":"Wu J, Kwong BY, Martires KJ, Rieger KE, Chung WH, Iyer GV, Lacouture ME. Granuloma annulare associated with immune checkpoint inhibitors. J Eur Acad Dermatol Venereol. 2018;32:124\u20136.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1477_CR25","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1111\/cup.13569","volume":"47","author":"T Hiraki","year":"2020","unstructured":"Hiraki T, Hatanaka M, Arimura A, Kawahira H, Kirishimal M, Kitazono I, Horinouchi M, Higashi M, Kanekura T, Tanimoto A. Granulomatous\/sarcoid-like reactions in the setting of programmed cell death-1 inhibition: a potential mimic of disease recurrence. J Cutan Pathol. 2020;47:154\u201360.","journal-title":"J Cutan Pathol"},{"key":"1477_CR26","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.2217\/imt-2018-0035","volume":"10","author":"MA Mitchell","year":"2018","unstructured":"Mitchell MA, Hogan K, Amjadi K. Atezolizumab-induced sarcoid-like granulomatous reaction in a patient with urothelial cell carcinoma. Immunotherapy. 2018;10:1189\u201392.","journal-title":"Immunotherapy"},{"key":"1477_CR27","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1111\/tbj.13386","volume":"25","author":"M Lafon","year":"2019","unstructured":"Lafon M, Blaye C, Kind M, Bechade D, Chassaigne F, Italiano A, Grellety T. Sarcoidosis-like reaction in metastatic triple negative breast cancer treated by anti-PD-L1. Breast J. 2019;25:971\u20133.","journal-title":"Breast J"},{"key":"1477_CR28","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1513\/AnnalsATS.201611-863LE","volume":"14","author":"R Balestra","year":"2017","unstructured":"Balestra R, Benzaquen S, Wang J. Sarcoidosis-like granulomatous lung reaction associated with anti-programmed death receptor-1 ligand therapy. Ann Am Thorac Soc. 2017;14:296\u20139.","journal-title":"Ann Am Thorac Soc"},{"key":"1477_CR29","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.arbres.2018.04.010","volume":"54","author":"IG Garc\u0131a-Manso","year":"2018","unstructured":"Garc\u0131a-Manso IG, del Mar Garda Rodenas M, Barroso Medel ME, Ill\u00e2n Gamb\u0131n FJ. Sarcoidosis-like granulomatous reaction associated with pembrolizumab immunotherapy. Sci Lett\/Arch Bronconeumol. 2018;54:592\u20133.","journal-title":"Sci Lett\/Arch Bronconeumol"},{"issue":"1","key":"1477_CR30","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.ad.2017.11.021","volume":"110","author":"J Cervantes","year":"2019","unstructured":"Cervantes J, Rosen A, Dehesa L, Dickinson G, Alonso-Llamazares J. Granulomatous reaction in a patient with metastatic melanoma treated with ipilimumab: first case reported with isolated cutaneous findings. Actas Dermosifiliogr. 2019;110(1):43\u20139.","journal-title":"Actas Dermosifiliogr"},{"key":"1477_CR31","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1002\/ccr3.2090","volume":"7","author":"AD Honigman","year":"2019","unstructured":"Honigman AD, Lai F, Elakis J, Prall O, Goh M, McCormack C. Pembrolizumab-induced sarcoid granulomatous panniculitis and bullous pemphigoid in a single patient. Clin Case Rep. 2019;7:773\u20135.","journal-title":"Clin Case Rep"},{"key":"1477_CR32","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1093\/annonc\/mdw125","volume":"27","author":"S Cousin","year":"2016","unstructured":"Cousin S, Toulmonde M, Kind M, Cazeau AL, Bechade D, Coindre JM, Italiano A. Pulmonary sarcoidosis induced by the anti-PD1 monoclonal antibody pembrolizumab. Ann Oncol. 2016;27:1178\u20139.","journal-title":"Ann Oncol"},{"key":"1477_CR33","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1177\/1078155216667635","volume":"23","author":"B Firwana","year":"2017","unstructured":"Firwana B, Ravilla R, Raval M, Hutchins L, Mahmoud F. Sarcoidosis-like syndrome and lymphadenopathy due to checkpoint inhibitors. J Oncol Pharm Pract. 2017;23:620\u20134.","journal-title":"J Oncol Pharm Pract"},{"key":"1477_CR34","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/s40425-016-0199-9","volume":"4","author":"JE Reuss","year":"2016","unstructured":"Reuss JE, Kunk PR, Stowman AM, Gru AA, Slingluff CL, Gaughan EM. Sarcoidosis in the setting of combination ipilimumab and nivolumab immunotherapy: a case report and review of the literature. J Immunother Cancer. 2016;4:94.","journal-title":"J Immunother Cancer"},{"key":"1477_CR35","first-page":"1355","volume":"32","author":"S Wigenhof","year":"2012","unstructured":"Wigenhof S, Mortion V, Seghers AC. Du four S, Wanderlinden E, Hanon S, Sarcoidosis in a patient with metastatic melanoma sequentially treated with anti-CTLA-4 monoclonal antibody and selective BRAF inhibit\u00f6r. Anticancer Res. 2012;32:1355\u20139.","journal-title":"Anticancer Res"},{"key":"1477_CR36","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1093\/ndt\/gfw467","volume":"32","author":"H Izzedine","year":"2017","unstructured":"Izzedine H, Mateus C, Boutros C, Robert C, Rouvier P, Amoura Z, Mathian A. Renal effects of immune checkpoint inhibitors. Nephrol Dial Transplant. 2017;32:936\u201342.","journal-title":"Nephrol Dial Transplant"},{"key":"1477_CR37","doi-asserted-by":"crossref","first-page":"954506","DOI":"10.4161\/21624011.2014.954506","volume":"3","author":"R Andersen","year":"2014","unstructured":"Andersen R, Norgaard P, Al-Jailawi MK, Svane IM. Late development of splenic sarcoidosis-like lesions in a patient with metastatic melanoma and long-lasting clinical response to ipilimumab. Oncoimmunology. 2014;3:954506.","journal-title":"Oncoimmunology"},{"key":"1477_CR38","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.jdcr.2019.04.006","volume":"5","author":"MLM van Baar","year":"2019","unstructured":"van Baar MLM, Guminski AD, Ferguson PM, Martin LK. Pembrolizumab for cutaneous squamous cell carcinoma: report of a case of inoperable squamous cell carcinoma with complete response to pembrolizumab complicated by granulomatous inflammation. JAAD Case Rep. 2019;5:491\u20134.","journal-title":"JAAD Case Rep"},{"key":"1477_CR39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40425-015-0105-x","volume":"4","author":"VH Koelzer","year":"2016","unstructured":"Koelzer VH, Rothschild SI, Zihler D, Wicki A, Willi B, Willi N, Voegeli M, Cathomas G, Zippelius A, Mertz KD. Systemic inflammation in a melanoma patient treated with immune checkpoint inhibitors\u2014an autopsy study. J Immunother Cancer. 2016;4:1\u20138.","journal-title":"J Immunother Cancer"},{"key":"1477_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.07.051","author":"CM Cornejo","year":"2018","unstructured":"Cornejo CM, Haun P, English J, Rosenbach M. Immune checkpoint inhibitors and the development of granulomatous reactions. J Am Acad Dermatol. 2018. https:\/\/doi.org\/10.1016\/j.jaad.2018.07.051.","journal-title":"J Am Acad Dermatol"},{"key":"1477_CR41","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1111\/cup.13150","volume":"45","author":"C Trinidad","year":"2018","unstructured":"Trinidad C, Nelson KC, Glitza Oliva IC, Torres-Cabala CA, Nagarajan P, Tetzlaff MT, Ivan D, Hwu WJ, Prieto VG, Curry JL, Aung PP. Dermatologic toxicity from immune checkpoint blockade therapy with an interstitial granulomatous pattern. J Cutan Pathol. 2018;45:504\u20137.","journal-title":"J Cutan Pathol"},{"key":"1477_CR42","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1200\/JCO.2011.39.3298","volume":"30","author":"G Berthol","year":"2012","unstructured":"Berthol G, Lazor R, Letonovic I, Romano E, Noirez L, Stalder JM, Speiser DE, Peters S, Michielin O. Pulmonary sarcoid-like granulomatosis induced by ipilimumab. J Clin Oncol. 2012;30:156\u20139.","journal-title":"J Clin Oncol"},{"key":"1477_CR43","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1111\/bjd.14808","volume":"176","author":"H Montaudie","year":"2017","unstructured":"Montaudie H, Pradelli J, Passeron T, Lacour JP, Leroy S. Pulmonary sarcoid-like granulomatosis induced by nivolumab. Br J Dermatol. 2017;176:1060\u20133.","journal-title":"Br J Dermatol"},{"key":"1477_CR44","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1159\/000362614","volume":"37","author":"KP Murphy","year":"2014","unstructured":"Murphy KP, Kennedy MP, Barry JE, O\u2019Regan KN, Power DG. New-onset mediastinal and central nervous system sarcoidosis in a patient with metastatic melanoma undergoing CTLA4 monoclonal antibody treatment. Oncol Res Treat. 2014;37:351\u20133.","journal-title":"Oncol Res Treat"},{"issue":"1","key":"1477_CR45","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s40425-018-0323-0","volume":"6","author":"MT Tetzlaff","year":"2018","unstructured":"Tetzlaff MT, Nelson KC, Diab A, Staerkel GA, Nagarajan P, Torres-Cabala CA, Chasen BA, Wargo JA, Prieto VG, Amaria RN, Curry JL. Granulomatous\/sarcoid-like lesions associated with checkpoint inhibitors: a marker of therapy response in a subset of melanoma patients. J Immunother Cancer. 2018;6(1):14.","journal-title":"J Immunother Cancer"},{"key":"1477_CR46","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1038\/cmi.2017.70","volume":"15","author":"Y Zhang","year":"2018","unstructured":"Zhang Y, Liu Z, Tian M, Hu X, Wang L, Ji J, Liao A. The altered PD-1\/PD-L1 pathway delivers the \u2018one-two punch\u2019 effects to promote the Treg\/Th17 imbalance in pre-eclampsia. Cell Mol Immunol. 2018;15:710\u201323.","journal-title":"Cell Mol Immunol"},{"key":"1477_CR47","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1097\/DAD.0000000000001066","volume":"40","author":"R Woodbeck","year":"2018","unstructured":"Woodbeck R, Metelitsa AI, Naert KA. Granulomatous tumoral melanosis associated with pembrolizumab therapy: a mimicker of disease progression in metastatic melanoma. Am J Dermatopathol. 2018;40:523\u20136.","journal-title":"Am J Dermatopathol"},{"key":"1477_CR48","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1634\/theoncologist.2016-0164","volume":"22","author":"GM O\u2019Kane","year":"2017","unstructured":"O\u2019Kane GM, Labre C, Doherty MK, Young K, Albal\u00e2 H, Leigbl NB. Monitoring and management of immune-related adverse events associated with programmed cell death protein-1 axis inhibitors in lung cancer. Oncologist. 2017;22:70\u201380.","journal-title":"Oncologist"},{"key":"1477_CR49","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1634\/theoncologist.2016-0055","volume":"21","author":"JS Weber","year":"2016","unstructured":"Weber JS, Postow M, Lao CD, Schadendorf D. Management of adverse events following treatment with anti-programmed death-1 agents. Oncologist. 2016;21:1230\u201340.","journal-title":"Oncologist"},{"key":"1477_CR50","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s13550-017-0258-3","volume":"7","author":"JP Crandall","year":"2017","unstructured":"Crandall JP, Tahari AK, Juergens RA, Brahmer JR, Rudin CM, Esposito G, Subramaniam DS, Knopp MV, Hall NC, Gajwani P, Leal JP, Lodge MA, Joo HO, Gabrielson EW, Shankar LK, Wahl RL. A comparison of FLT to FDGPET\/CT in the early assessment of chemotherapy response in stages IB\u2013IIIA resectable NSCLC. EJNMMI Res. 2017;7:8.","journal-title":"EJNMMI Res"},{"key":"1477_CR51","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/RLU.0000000000002967","volume":"45","author":"R Yeh","year":"2020","unstructured":"Yeh R, Trager MH, Rizk ME, Finkel GG, Barker LW, Carvajal RD, Geskin LJ, Schwartz GK. FLT-PET at 6 weeks predicts response assessed by CT at 12 weeks in melanoma patients treated with pembrolizumab. Clin Nucl Med. 2020;45:267\u201377.","journal-title":"Clin Nucl Med"},{"key":"1477_CR52","doi-asserted-by":"crossref","first-page":"5014","DOI":"10.1158\/0008-5472.CAN-12-0635","volume":"72","author":"Z Li","year":"2012","unstructured":"Li Z, Graf N, Herrmann K, J\u00fcnger A, Aichler M, Feuchtinger A, Baumgart A, Walch A, Peschel C, Schwaiger M, Buck A, Keller U, Dechow T. FLT-PET is superior to FDG-PET for very early response prediction in NPM-ALK-positive lymphoma treated with targeted therapy. Cancer Res. 2012;72:5014\u201324.","journal-title":"Cancer Res"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-021-01477-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12032-021-01477-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-021-01477-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,18]],"date-time":"2022-12-18T05:18:40Z","timestamp":1671340720000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12032-021-01477-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,18]]},"references-count":52,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["1477"],"URL":"https:\/\/doi.org\/10.1007\/s12032-021-01477-y","relation":{},"ISSN":["1357-0560","1559-131X"],"issn-type":[{"value":"1357-0560","type":"print"},{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,18]]},"assertion":[{"value":"4 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"There is no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"29"}}